NCT06356675View on ClinicalTrials.gov

A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

July 1, 2028

Study Completion Date

July 1, 2028

Conditions
Advanced NSCLC
Interventions
DRUG

Tislelizumab

200mg iv D1 Q3W

DRUG

Anlotinib

Anlotinib 12mg D1-12 Q3W

All Listed Sponsors
lead

The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine

OTHER

NCT06356675 - A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy | Biotech Hunter | Biotech Hunter